Skip to content

Study · Not a test of the peptide alone · 1996

2 results

Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.

Korbonits M, Little JA, Camacho-Hübner C, Trainer PJ, Besser GM, Grossman AB

Growth regulation1 Jun 1996Cited by 6 (Europe PMC)

PMID8781987 (opens in a new tab)PepBankPUB-08781987

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneEx vivo tissueMechanism

    In rat hypothalamic tissue, results suggested that simultaneous activation of both IGF receptor types was needed for IGF inhibition of GHRH release.

    In plain wordsIn lab tests with rat tissue, results suggested that IGF inhibition of GHRH release required activation of both IGF receptor types.

    Outcome
    DecreaseGHRH release
    Study

    ratn: not reported in source

    In vitro hypothalamic tissue
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Our results suggest that the simultaneous activation of type 1 and type 2 IGF receptors is needed for the negative feedback effect of IGFs on GHRH release in this in vitro system, in agreement with earlier findings in vivo.
    1 context sentence
    Summary · context
    This study was designed to investigate the feedback loop between insulin-like growth factor-I (IGF-I) and IGF-II and the hypothalamic hormones growth hormone-releasing hormone (GHRH) and somatostatin (SS) using an in vitro rat hypothalamic model.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneEx vivo tissueMechanism

    In rat hypothalamic tissue, none of the tested peptide combinations altered somatostatin release.

    In plain wordsIn lab tests with rat tissue, none of the tested peptide combinations changed somatostatin release.

    Outcome
    No significant changeSomatostatin release
    Study

    ratn: not reported in source

    In vitro hypothalamic tissue
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Somatostatin was not altered by any combination of peptides.
    1 context sentence
    Summary · context
    This study was designed to investigate the feedback loop between insulin-like growth factor-I (IGF-I) and IGF-II and the hypothalamic hormones growth hormone-releasing hormone (GHRH) and somatostatin (SS) using an in vitro rat hypothalamic model.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.